secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVO Fertility, Inc. (IVF)
CIK:        0001417926
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001493152-24-032181
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INVO Bioscience Q2 2024 revenue surged 481% to $1.84M; adjusted EBITDA improved by $1.1M to $(0.5)M
--------------------------------------------------------------------------------

- Revenue $1,836,597, up 481% YoY ($315,902); clinic revenue up 611% to $1,807,921.
- Net loss remained $(2.2) million; total operating expenses rose to $3.7M, including $1.0M non-cash expense.
- Adjusted EBITDA improved to $(0.5) million from $(1.6) million in Q2 2023.
- All three fertility centers (Middleton, Atlanta, Birmingham) reported sequential revenue growth and are collectively profitable.
- Merger with NAYA Biosciences (all-stock) still in discussions for further extension; $25K in transaction costs incurred in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417926/000149315224032181/0001493152-24-032181-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417926/000149315224032181/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-032181

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer